218 related articles for article (PubMed ID: 20352624)
1. Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia.
Liu R; Zhou Q; La Cava A; Campagnolo DI; Van Kaer L; Shi FD
Eur J Immunol; 2010 Jun; 40(6):1577-89. PubMed ID: 20352624
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis.
Aricha R; Feferman T; Fuchs S; Souroujon MC
J Immunol; 2008 Feb; 180(4):2132-9. PubMed ID: 18250419
[TBL] [Abstract][Full Text] [Related]
3. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis.
Aricha R; Mizrachi K; Fuchs S; Souroujon MC
J Autoimmun; 2011 Mar; 36(2):135-41. PubMed ID: 21193288
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2/anti-interleukin-2 monoclonal antibody immune complex suppresses collagen-induced arthritis in mice by fortifying interleukin-2/STAT5 signalling pathways.
Lee SY; Cho ML; Oh HJ; Ryu JG; Park MJ; Jhun JY; Park MK; Stone JC; Ju JH; Hwang SY; Park SH; Surh CD; Kim HY
Immunology; 2012 Dec; 137(4):305-16. PubMed ID: 23167249
[TBL] [Abstract][Full Text] [Related]
5. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis.
Dinh TN; Kyaw TS; Kanellakis P; To K; Tipping P; Toh BH; Bobik A; Agrotis A
Circulation; 2012 Sep; 126(10):1256-66. PubMed ID: 22851544
[TBL] [Abstract][Full Text] [Related]
6. IL-2 contributes to maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection.
Berretta F; St-Pierre J; Piccirillo CA; Stevenson MM
J Immunol; 2011 Apr; 186(8):4862-71. PubMed ID: 21389253
[TBL] [Abstract][Full Text] [Related]
7. Suppression of murine allergic airway disease by IL-2:anti-IL-2 monoclonal antibody-induced regulatory T cells.
Wilson MS; Pesce JT; Ramalingam TR; Thompson RW; Cheever A; Wynn TA
J Immunol; 2008 Nov; 181(10):6942-54. PubMed ID: 18981114
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T cells in multiple sclerosis and myasthenia gravis.
Danikowski KM; Jayaraman S; Prabhakar BS
J Neuroinflammation; 2017 Jun; 14(1):117. PubMed ID: 28599652
[TBL] [Abstract][Full Text] [Related]
9. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells.
Wang W; Milani M; Ostlie N; Okita D; Agarwal RK; Caspi RR; Conti-Fine BM
J Immunol; 2007 Jun; 178(11):7072-80. PubMed ID: 17513756
[TBL] [Abstract][Full Text] [Related]
10. In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy.
Liu CL; Ye P; Yen BC; Miao CH
Mol Ther; 2011 Aug; 19(8):1511-20. PubMed ID: 21468007
[TBL] [Abstract][Full Text] [Related]
11. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia.
Liu R; La Cava A; Bai XF; Jee Y; Price M; Campagnolo DI; Christadoss P; Vollmer TL; Van Kaer L; Shi FD
J Immunol; 2005 Dec; 175(12):7898-904. PubMed ID: 16339525
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2/Anti-Interleukin-2 Immune Complex Attenuates Cardiac Remodeling after Myocardial Infarction through Expansion of Regulatory T Cells.
Zeng Z; Yu K; Chen L; Li W; Xiao H; Huang Z
J Immunol Res; 2016; 2016():8493767. PubMed ID: 27144181
[TBL] [Abstract][Full Text] [Related]
13. Anti-IL-2 treatment impairs the expansion of T(reg) cell population during acute malaria and enhances the Th1 cell response at the chronic disease.
Zago CA; Bortoluci KR; Sardinha LR; Pretel FD; Castillo-Méndez SI; Freitas do Rosário AP; Hiyane MI; Muxel SM; Rodriguez-Málaga SM; Abrahamsohn IA; Álvarez JM; D'Império Lima MR
PLoS One; 2012; 7(1):e29894. PubMed ID: 22272258
[TBL] [Abstract][Full Text] [Related]
14. IL-2-Anti-IL-2 Monoclonal Antibody Immune Complexes Inhibit Collagen-Induced Arthritis by Augmenting Regulatory T Cell Functions.
Yokoyama Y; Iwasaki T; Kitano S; Satake A; Nomura S; Furukawa T; Matsui K; Sano H
J Immunol; 2018 Oct; 201(7):1899-1906. PubMed ID: 30143591
[TBL] [Abstract][Full Text] [Related]
15. Selective stimulation of T cell subsets with antibody-cytokine immune complexes.
Boyman O; Kovar M; Rubinstein MP; Surh CD; Sprent J
Science; 2006 Mar; 311(5769):1924-7. PubMed ID: 16484453
[TBL] [Abstract][Full Text] [Related]
16. T-bet deficiency decreases susceptibility to experimental myasthenia gravis.
Liu R; Hao J; Dayao CS; Shi FD; Campagnolo DI
Exp Neurol; 2009 Dec; 220(2):366-73. PubMed ID: 19818352
[TBL] [Abstract][Full Text] [Related]
17. Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis.
Thiruppathi M; Sheng JR; Li L; Prabhakar BS; Meriggioli MN
J Autoimmun; 2014 Aug; 52():64-73. PubMed ID: 24388113
[TBL] [Abstract][Full Text] [Related]
18. Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis.
Mu L; Sun B; Kong Q; Wang J; Wang G; Zhang S; Wang D; Liu Y; Liu Y; An H; Li H
Immunology; 2009 Sep; 128(1 Suppl):e826-36. PubMed ID: 19740344
[TBL] [Abstract][Full Text] [Related]
19. IL-2/anti-IL-2 complexes ameliorate lupus nephritis by expansion of CD4
Yan JJ; Lee JG; Jang JY; Koo TY; Ahn C; Yang J
Kidney Int; 2017 Mar; 91(3):603-615. PubMed ID: 27914701
[TBL] [Abstract][Full Text] [Related]
20. Suppression of experimental autoimmune myasthenia gravis by autologous T regulatory cells.
Aricha R; Reuveni D; Fuchs S; Souroujon MC
J Autoimmun; 2016 Feb; 67():57-64. PubMed ID: 26489998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
